GLIBK:NASDAQGCI Liberty, Inc. - Series C GCI Group Analysis
Data as of 2026-04-06 - not real-time
$37.02
Latest Price
5/10Risk
Risk Level: Medium
Executive Summary
GCI Liberty (GLIBK) is trading at $37.02, just below the calculated resistance of $37.96 and modestly above the 20‑day SMA ($36.76) while still under the 50‑day SMA ($37.79), indicating a neutral price trend. Technical momentum is slightly bullish, with the MACD line crossing above its signal and a positive histogram, and the RSI sits near the midpoint at 48.7, suggesting no immediate overbought pressure.
Fundamentally, the stock appears undervalued – the price‑to‑book ratio of 0.87 and a DCF‑derived fair value of $39.95 imply a discount to intrinsic value. However, profitability is weak, with a trailing EPS of –$9.97, a negative net profit margin (‑29.5%), and a negative ROE (‑19.7%). The company generates solid operating cash flow ($370 M) and free cash flow ($170 M), but carries a high debt load ($1.12 B) and a debt‑to‑equity ratio of 65.8, offset by $416 M in cash. Volatility is elevated at 23% over the past 30 days, though beta is low (0.51), and market sentiment is in “Extreme Greed” mode (78.8 on the Fear & Greed Index). Recent news is limited to routine corporate communications (2026 virtual annual meeting) and a mention of a 2025 stock surge, offering little substantive catalyst.
Fundamentally, the stock appears undervalued – the price‑to‑book ratio of 0.87 and a DCF‑derived fair value of $39.95 imply a discount to intrinsic value. However, profitability is weak, with a trailing EPS of –$9.97, a negative net profit margin (‑29.5%), and a negative ROE (‑19.7%). The company generates solid operating cash flow ($370 M) and free cash flow ($170 M), but carries a high debt load ($1.12 B) and a debt‑to‑equity ratio of 65.8, offset by $416 M in cash. Volatility is elevated at 23% over the past 30 days, though beta is low (0.51), and market sentiment is in “Extreme Greed” mode (78.8 on the Fear & Greed Index). Recent news is limited to routine corporate communications (2026 virtual annual meeting) and a mention of a 2025 stock surge, offering little substantive catalyst.
Market Outlook
Short Term
< 1 yearNeutral
Model confidence: 5/10
Key Factors
- Price near resistance with neutral trend
- Bullish MACD signal but weak earnings
- Stable volume and low beta mitigate short‑term downside
Medium Term
1–3 yearsPositive
Model confidence: 6/10
Key Factors
- Discount to book value and DCF fair value
- Positive operating cash flow despite net loss
- Potential upside if earnings turnaround occurs
Long Term
> 3 yearsNeutral
Model confidence: 5/10
Key Factors
- High debt burden may limit growth
- No dividend and negative EPS reduce income appeal
- Valuation cushion from low price‑to‑book offers downside protection
Key Metrics & Analysis
Financial Health
Revenue Growth-0.40%
Profit Margin-29.54%
ROE-19.71%
ROA3.36%
Debt/Equity65.83
P/B Ratio0.9
Op. Cash Flow$370.0M
Free Cash Flow$170.1M
Industry P/E17.3
Technical Analysis
TrendNeutral
RSI48.7
Support$35.13
Resistance$37.96
MA 20$36.76
MA 50$37.79
MA 200$36.07
MACDBullish
VolumeStable
Fear & Greed Index78.8
Valuation
Fair Value$39.95
GradeUndervalued
TypeValue
Risk Assessment
Beta0.51
Volatility23.15%
Sector RiskMedium
Reg. RiskMedium
Geo RiskMedium
Currency RiskLow
Liquidity RiskMedium
Similar Tickers
This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.